Cellomatics BioSciences

Cellomatics Biosciences is a privately held, laboratory-based CRO founded in 2015 (operating from 2017) and headquartered in Nottingham, UK. It provides specialized, bespoke bioassay services to support preclinical drug development for small to medium-sized biotechs and pharma companies. The company's core expertise lies in developing complex in vitro models (monocultures, co-cultures, 3D cultures) within key therapeutic areas, aiming to expedite client R&D through a consultative and innovative approach. As a service provider, it is revenue-generating but does not develop its own therapeutic pipeline.

Expertise in developing bespoke, complex in vitro cell-based assays including monocultures, co-cultures, and 3D cultures to replicate in vivo physiology for preclinical drug discovery support.

Cellomatics competes in the fragmented preclinical CRO market against large global players (e.g., LabCorp, Charles River) and numerous specialized boutique labs. Its differentiation is a deep focus on bespoke assay development in specific therapeutic areas and a consultative, flexible service model tailored for small-to-mid-sized biotechs.